AlloVir Q3 EPS $(0.50) Up From $(0.72) YoY
AlloVir (NASDAQ:ALVR) reported quarterly losses of $(0.50) per share. This is a 30.56 percent increase over losses of $(0.72) per share from the same period last year.
Leading Independent Proxy Advisory Firm ISS Recommends Avalara Shareholders Vote “FOR” The Transaction With Vista Equity Partners
Avalara Urges Shareholders to Vote "FOR" Value Maximizing Transaction on WHITE Proxy Card
Morgan Stanley Maintains Overweight on AlloVir, Lowers Price Target to $27
Morgan Stanley analyst Matthew Harrison maintains AlloVir (NASDAQ:ALVR) with a Overweight and lowers the price target from $32 to $27.
Why FlexShopper Surged Over 47%; Here Are 104 Biggest Movers From Yesterday
Gainers
Digital Media Solutions, Inc. (NYSE: DMS) jumped 78.8% to close at $2.11. Digital Media Solutions recently reported worse-than-expected Q2 EPS and sales results.
Why Matterport Is Trading Higher By Around 25%, Here Are 73 Stocks Moving In Thursday’s Mid-Day Session
Gainers
Timber Pharmaceuticals, Inc. (NYSE: TMBR) shares rose 63.8% to $0.1769. Timber Pharmaceuticals recently announced closing of $8.0 million public offering.
Why Avalo Therapeutics Surged 32%; Here Are 111 Biggest Movers From Yesterday
Gainers
AeroClean Technologies, Inc. (NASDAQ: AERC) gained 60.1% to settle at $7.27 on Tuesday after the company was granted US patent for an air treatment system and method.
Why Verona Pharma Is Trading Higher By Around 84%, Here Are 85 Stocks Moving In Tuesday’s Mid-Day Session
Gainers
Verona Pharma plc (NASDAQ: VRNA) shares jumped 83.6% to $12.70 after the company announced ensifentrine met its primary endpoint and secondary endpoints in the Phase 3 ENHANCE-2 trial for COPD. The company also reported Q2 earnings results.
